SOPHiA GENETICS (SOPH) chair sells 20,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported selling 20,000 Ordinary Shares on 2026-08-04 in an open-market transaction under a duly adopted Rule 10b5-1(c) trading plan. The shares were sold at a weighted average price of $6.9206, within a $6.90–$6.98 range, leaving him with 3,472,822 shares held directly.

Insider Trade Summary 10b5-1

Net Seller: 20,000 shares

Net Sell 1 txn

Insider Camblong Jurgi

Role Executive Chairman

Sold 20,000 shs ($138K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F2	20,000	$6.9206	$138K

Holdings After Transaction: Ordinary Shares — 3,472,822 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.90 to $6.98, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 20,000 Ordinary Shares Weighted average sale price: $6.9206 per share Sale price range: $6.90–$6.98 per share +2 more

5 metrics

Shares sold 20,000 Ordinary Shares Open-market sale on 2026-08-04 by Executive Chairman Jurgi Camblong

Weighted average sale price $6.9206 per share Weighted average price for the 20,000 shares sold

Sale price range $6.90–$6.98 per share Range of individual transaction prices for the sold shares

Shares after transaction 3,472,822 shares Direct Ordinary Share holdings following the reported sale

Rule 10b5-1 status Affirmed under Rule 10b5-1(c) Transaction made pursuant to a duly adopted trading plan

Key Terms

Rule 10b5-1(c), weighted average price, Ordinary Shares

3 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Ordinary Shares financial

"security_title: Ordinary Shares, transaction_date: 2026-08-04"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 04:14 PM Accepted by SEC EDGAR 08/05/2026 - 04:14 PM Learn about SEC filing dates

FAQ

What insider transaction did SOPHiA GENETICS (SOPH) report for Jurgi Camblong?

Jurgi Camblong reported selling 20,000 Ordinary Shares of SOPHiA GENETICS on 2026-08-04. The sale was executed as an open-market transaction under a duly adopted Rule 10b5-1(c) trading plan, indicating it was pre-arranged rather than a discretionary trade.

At what price were the SOPHiA GENETICS (SOPH) shares sold in this Form 4?

The shares were sold at a weighted average price of $6.9206 per share. According to the filing, individual trades occurred in multiple transactions at prices ranging from $6.90 to $6.98, and detailed price breakdowns are available upon written request.

How many SOPHiA GENETICS (SOPH) shares does Jurgi Camblong hold after this sale?

After the reported sale, Jurgi Camblong directly holds 3,472,822 Ordinary Shares of SOPHiA GENETICS. This figure reflects the position immediately following the 20,000-share disposition disclosed in the Form 4 and represents his continuing direct ownership stake.

Was the SOPHiA GENETICS (SOPH) insider sale made under a Rule 10b5-1 trading plan?

Yes, the sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan. The filing’s checkbox and footnote both confirm the pre-arranged plan, which is designed to permit scheduled trades regardless of subsequent possession of material nonpublic information.

What does the price range disclosed in the SOPHiA GENETICS (SOPH) Form 4 mean?

The filing lists a weighted average price of $6.9206 and a range of $6.90–$6.98. This means the 20,000 shares were sold in multiple trades across that price band, and the insider offers to provide exact trade-by-trade prices upon written request.

Who is the insider involved in the latest SOPHiA GENETICS (SOPH) Form 4 filing?

The insider is Jurgi Camblong, who serves as Executive Chairman and director of SOPHiA GENETICS SA. He reported a single open-market sale of 20,000 Ordinary Shares, executed under a Rule 10b5-1 trading plan, with substantial direct holdings remaining afterward.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Camblong Jurgi

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/04/2026		S		20,000(1)	D	$6.9206(2)	3,472,822	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.90 to $6.98, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)